人参皂苷Rg3配合化疗对中晚期非小细胞肺癌患者血清中TGF-α、TGF-β1和VEGF的影响

摘要

Objective To observe the effect of ginsenoside Rg 3 combined with chemotherapy on VEGF , TGF-β1 and TGF-αin serum of patients with middle and advanced stage non-small cell lung cancer , and to evaluate its effect on non-small cell lung cancer .Methods The clinical staging ( TNM) of 93 ⅢA-Ⅳ patients with NSCLC in our hospital from 2010 to 2013 were randomly divided into the control group (n=46) and the observation group (n=47).All patients were treated with GP for 4 courses, 3 weeks per course, and the observation group was given 2 Senyi capsules per time , twice a day for 2 courses .The change of KPS score and body weight were recorded and com-pared with the changes of VEGF , TGF-β1 and TGF-αin serum of the 2 groups before and after treatment .Results After treatment, the level of VEGF in serum decreased in the two groups (P<0.05), and the decrease was more pronounced in the observation group than in the control group (P<0.05), while the TGF-αand TGF-β1 in the con-trol group were significantly lower than those before treatment (P<0.05).After treatment, the change of KSP score and body weight of the 2 groups were significantly different ( P<0.05 ) , and the score of the observation group was significantly better than that of the control group ( P<0.05 ) .The incidence of adverse reactions in the observation group was significantly lower than that in the control group .Conclusion Ginsenoside Rg3 combined with chemother-apy can reduce the serum TGF-αand TGF-β1 and VEGF and promote tumor cell apoptosis in the treatment of ad-vanced non small cell lung cancer , which plays a role in reducing toxicity .%目的：观察人参皂苷Rg3配合化疗对中晚期非小细胞肺癌患者血清中TGF-α、TGF-β1和VEGF的影响，评价其对非小细胞肺癌的疗效。方法筛选2010年-2013年来我院肿瘤科病房及门诊就诊的临床分期（ TNM）为ⅢA-Ⅳ期的非小细胞肺癌患者93例，随机分到对照组和观察组中，对照组46例，观察组47例。对照组患者采取GP方案进行化疗，不给予针对性治疗，3周为1个疗程，化疗周期为4个疗程，进行定期复查及随访；观察组患者化疗方案同对照组一致，3周为1个疗程，化疗周期为4个疗程，并在化疗前3天开始服用参一胶囊，饭前空腹口服，一次2粒，一日2次，2个月为1个疗程，连续服用2个疗程，之后进行定期复查及随访。记录治疗过程中KPS评分变化、体重的变化，比较治疗前后两组患者血清中TGF-α、TGF-β1和VEGF的变化。结果治疗后两组患者血清中VEGF含量均有所降低（ P＜0.05），并且治疗后观察组患者的VEGF水平显著低于对照组（ P＜0.05）；对照组患者血清中的TGF-α、TGF-β1含量治疗后与治疗前比较没有显著差异（ P＞0.05），而观察组的TGF-α、TGF-β1水平较治疗前显著降低（ P＜0.05）。治疗后两组病例的KSP评分变化及体重变化均差异显著（ P＜0.05），观察组的评分变化及体重变化明显优于对照组，两组比较差异有统计意义（ P＜0.05）；观察组的不良反应例数明显少于对照组。结论人参皂苷Rg3配合化疗方案治疗晚期非小细胞肺癌，可以降低患者血清中TGF-α、TGF-β1和VEGF，促使肿瘤细胞凋亡，起到减毒增效的作用。